Group A Beta Hemolytic Streptococci (GAS) is essentially the most essential human pathogen that results in tonsillopharyngitis. The goals of this examine have been to determine GAS isolates and to find out emm typing, the protection price of accessible vaccines, and the distribution of superantigen gene profiles. 15 GAS isolates have been remoted from throat cultures of 200 sufferers with tonsillopharyngitis, who have been admitted to Canakkale Well being Software and Analysis Hospital between October 2017 and Might 2018.
Identification of the isolates was carried out by typical strategies and 16S rRNA sequence evaluation. emm typing and exotoxin profiling of the isolates have been carried out by polymerase chain response. 7.5% GAS was detected in 200 sufferers. All of the GAS isolates have been recognized as S. pyogenes. emm typing might be carried out in 13 S. pyogenes isolates. emm89 (33.3%), emm44 (20%), emm6 (13.3%), emm84 (6.7%), emm1 (6.7%), and emm18.1 (6.7%) have been discovered to be six emm sorts.
The protection price of S. pyogenes strains for 26-valent vaccine was 61.5% and for the 30-valent vaccine 84.6%. The most typical exotoxin was speB (86.7%), adopted by speC (60%), speF (33.3%), ssa (26.7%), speA (20%), speM (20%), speJ (13.3%), speL (6.7%), and speI (6.7%). Because of figuring out the emm sorts of S. pyogenes species in Canakkale, it was concluded that the potential of 30-valent vaccine needs to be thought-about in Turkey and growth of vaccines containing exotoxin sorts could also be helpful.
Up to date emm-typing protocol for Streptococcus pyogenes.
PCR-based typing of the emm gene Streptococcus pyogenes typically leads to the amplification of a number of bands. This has resulted within the misclassification of strains into sorts based mostly on non-emm gene sequences. We aimed to enhance the specificity of the emm typing PCR response utilizing a primer referred to as CDC3, the sequence for which has been beforehand used to determine emm genes in silico.The proposed primer CDC3 was validated in silico from a worldwide database of 1688 GAS genomes and in vitro with 32 isolates.
PCR reactions have been carried out on genomic DNA from every isolate, utilizing the revealed CDC1 ahead primer with the CDC2 reverse primer or the brand new CDC3 reverse primer. The merchandise have been examined by gel electrophoresis, and consultant PCR merchandise have been sequenced.In 1,688 S. pyogenes genomes, the earlier CDC2 reverse primer annealed in silico in 1,671 emm genes and likewise in 2,109 non emm genes in shut proximity, whereas the brand new CDC3 primer annealed in 1,669 emm genes solely.
The remaining 19 genes and not using a CDC3 binding web site have been chimeric emm genes. The PCR pair CDC1+CDC3 produced a single band at applicable molecular weight in all 32 isolates examined, whereas the CDC1+CDC2 pair produced greater than 1 band in 13 of 32 isolates (40%).The brand new CDC3 primer is extra particular for emm genes than the earlier CDC2 primer and represents a easy resolution to scale back the potential for mistyping S. pyogenes strains.
Distribution of emm sorts and macrolide resistance determinants amongst group A streptococci within the Center East and North Africa.
This evaluate aimed to supply an up to date situation of the Group A Streptococcus (GAS) epidemiology within the Center Japanese and North African (MENA) area with a particular highlight on essentially the most prevalent emm sorts and macrolide resistance profiles.
Whereas the burden of invasive GAS infections is elusive to evaluate within the MENA area, the GAS prevalence ranged from 2.5% to up 42.4% in pharyngitis sufferers and from 2.4% to up 35.4% in wholesome carriers. emm1, emm12, emm89, emm4, emm28, and emm3 have been chargeable for the key GAS burden within the MENA area. The protection price of the brand new M-protein based mostly vaccine candidate (30-valent) diversified from 42% to 100% based on the nations.
The speed of erythromycin resistance differed considerably between nations the place values differed from low, reasonable, to excessive. Our information add extra shreds of proof on the uncared for GAS burden within the MENA area. Systematic surveillance of invasive GAS infections together with a molecular characterization of GAS isolates are strongly really useful to trace the developments of circulating clones and consider the potential protection of the vaccine candidates.
Adjustments over an 8-year interval in Streptococcus pyogenes emm sorts in pharyngeal isolates from non-invasive an infection sufferers at a pediatric facility.
Streptococcus pyogenes, or Group A Streptococcus (GAS), is among the commonest pathogens of bacterial an infection in youngsters. GAS may cause such non-serious and non-invasive illnesses as pharyngitis and pores and skin infections, in addition to severe and invasive illnesses like streptococcal poisonous shock syndrome. One of many elements that make GAS pathogenic is the type-specific M protein discovered on the cell floor. In 2008, we examined GAS strains remoted from sufferers with non-invasive infections at our hospital to investigate the emm sorts and their traits.
The current examine was performed Eight years later for comparability.The 23 examine topics have been in sufferers or out sufferers at Nippon Medical College’s Tama Nagayama Hospital between 2016 and 2017. A pharyngeal swab have been taken from every topics. Genes encording M proteins have been amplified by polymerase chain response.The emm kind evaluation recognized emm1 in 11 of the 23 strains and emm12 in 4. The three GGS strains carried the M-like protein genes.
Anti-human CD22 Monoclonal Antibody PerCP-Cy5.5 Conjugated, Flow Validated |
|||
| FC01572-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 240 EUR |
|
Description: Mouse Monoclonal human CD22 Antibody PerCP-Cy5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
|||
Anti-human CD8 Monoclonal Antibody PerCP-Cy5.5 Conjugated, Flow Validated |
|||
| FC02236-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 240 EUR |
|
Description: Mouse Monoclonal human CD8 Antibody PerCP-Cy5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
|||
Anti-human CD13 Monoclonal Antibody PerCP-Cy5.5 Conjugated, Flow Validated |
|||
| FC02591-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 240 EUR |
|
Description: Mouse Monoclonal human CD13 Antibody PerCP-Cy5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
|||
Anti-human CD3 Monoclonal Antibody PerCP-Cy5.5 Conjugated, Flow Validated |
|||
| FC02675-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 192 EUR |
|
Description: Mouse Monoclonal human CD3 Antibody PerCP-Cy5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
|||
Anti-human CD10 Monoclonal Antibody PerCP-Cy5.5 Conjugated, Flow Validated |
|||
| FC04065-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 199.2 EUR |
|
Description: Mouse Monoclonal human CD10 Antibody PerCP-Cy5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
|||
Anti-human HLA-DR Monoclonal Antibody PerCP-Cy5.5 Conjugated, Flow Validated |
|||
| FC00568-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 240 EUR |
|
Description: Mouse Monoclonal human HLA-DR Antibody PerCP-Cy5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
|||
Anti-human CD20 PerCP Monoclonal Antibody PerCP Cy5.5 Conjugated, Flow Validated |
|||
| FC03780-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 240 EUR |
|
Description: Mouse Monoclonal human CD20 PerCP Antibody PerCP Cy5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
|||
Mouse anti-human CD7 Monoclonal Antibody PerCP-Cy5.5 Conjugated, Flow Validated |
|||
| FC01974-1-PerCP-Cy5.5 | BosterBio | 25 Tests, 100 Tests, 200 Tests | 240 EUR |
|
Description: Mouse Mouse Monoclonal Anti-human CD7 PerCP-Cy5.5 Conjugated, designed for Flow Cytometry and validated by Flow Cytometry using Human cells. |
|||
Anti-Mouse CD3e Monoclonal Antibody PerCP-Cyanine5.5 Conjugated, Flow Validated |
|||
| FC04405-PerCP-Cy5.5 | BosterBio | 25ug, 100ug | 157.2 EUR |
|
Description: Hamster Monoclonal Mouse CD3e Antibody PerCP-Cyanine5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Mouse. |
|||
CY5.5-COOH |
|||
| abx187851-1g | Abbexa | 1 g | 2197.2 EUR |
CY5.5-PEG-NH2,2K |
|||
| FL079005-10K-50mg | Biochempeg | 50mg | 564 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-NH2,2K |
|||
| FL079005-20K-50mg | Biochempeg | 50mg | 564 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-NH2,2K |
|||
| FL079005-2K-50mg | Biochempeg | 50mg | 564 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-NH2,2K |
|||
| FL079005-3.4K-50mg | Biochempeg | 50mg | 564 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-NH2,2K |
|||
| FL079005-5K-50mg | Biochempeg | 50mg | 564 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-N3,2K |
|||
| FL079006-2K-50mg | Biochempeg | 50mg | 564 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
APC-Cy5.5 Tandem |
|||
| 2622 | AAT Bioquest | 1 mg | 262.8 EUR |
DSPE-PEG-CY5.5 |
|||
| abx085192-10kDa100mg | Abbexa | 10 kDa; 100 mg | 1328.4 EUR |
DSPE-PEG-CY5.5 |
|||
| abx085192-2kDa100mg | Abbexa | 2 kDa; 100 mg | 1328.4 EUR |
DSPE-PEG-CY5.5 |
|||
| abx085192-5kDa100mg | Abbexa | 5 kDa; 100 mg | 1328.4 EUR |
CY5.5-PEG-SH |
|||
| abx085229-10kDa50mg | Abbexa | 10 kDa; 50 mg | 961.2 EUR |
CY5.5-PEG-SH |
|||
| abx085229-1kDa50mg | Abbexa | 1 kDa; 50 mg | 961.2 EUR |
CY5.5-PEG-SH |
|||
| abx085229-2kDa50mg | Abbexa | 2 kDa; 50 mg | 961.2 EUR |
CY5.5-PEG-SH |
|||
| abx085229-34kDa50mg | Abbexa | 3.4 kDa; 50 mg | 961.2 EUR |
CY5.5-PEG-SH |
|||
| abx085229-5kDa50mg | Abbexa | 5 kDa; 50 mg | 961.2 EUR |
CY5.5-PEG-FA |
|||
| abx085302-10kDa100mg | Abbexa | 10 kDa; 100 mg | 1328.4 EUR |
CY5.5-PEG-FA |
|||
| abx085302-2kDa100mg | Abbexa | 2 kDa; 100 mg | 1328.4 EUR |
CY5.5-PEG-FA |
|||
| abx085302-34kDa100mg | Abbexa | 3.4 kDa; 100 mg | 1328.4 EUR |
CY5.5-PEG-FA |
|||
| abx085302-5kDa100mg | Abbexa | 5 kDa; 100 mg | 1328.4 EUR |
CY5.5-PEG-NH2 |
|||
| abx085367-10kDa50mg | Abbexa | 10 kDa; 50 mg | 655.2 EUR |
CY5.5-PEG-NH2 |
|||
| abx085367-20kDa50mg | Abbexa | 20 kDa; 50 mg | 655.2 EUR |
CY5.5-PEG-NH2 |
|||
| abx085367-2kDa50mg | Abbexa | 2 kDa; 50 mg | 627.6 EUR |
CY5.5-PEG-NH2 |
|||
| abx085367-5kDa50mg | Abbexa | 5 kDa; 50 mg | 646.8 EUR |
CY5.5-PEG-N3 |
|||
| abx085404-2kDa50mg | Abbexa | 2 kDa; 50 mg | 627.6 EUR |
Streptavidin-Cy5.5 conjugate |
|||
| SV-C5-100 | Alpha Diagnostics | 100 tests | 242.4 EUR |
PerCP-Cy5.5 Tandem |
|||
| 2650 | AAT Bioquest | 1 mg | 211 EUR |
Cy5.5 biotin conjugate |
|||
| 3105 | AAT Bioquest | 5 mg | 211 EUR |
Anti-Mouse CD8a Monoclonal Antibody PerCP-Cyanine5.5 Conjugated, Flow Validated |
|||
| FC02236-1-PerCP-Cy5.5 | BosterBio | 25ug, 100ug | 213.6 EUR |
|
Description: Rat Monoclonal Mouse CD8a Antibody PerCP-Cyanine5.5 Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Mouse. |
|||
Cy5.5 azide (non-sulfonated) |
|||
| A8114-25 | ApexBio | 25 mg | 1939.2 EUR |
|
Description: This Cy5.5 is a labeling reagent that ready for the use in Click Chemistry reaction which available as 10 mM solution in DMSO. As Cy5.5 azide is a far-red emitting dye, it can replace Alexa Fluor 680, and DyLight 680. |
|||
Cy5.5 azide (non-sulfonated) |
|||
| A8114-5 | ApexBio | 5 mg | 699.6 EUR |
|
Description: This Cy5.5 is a labeling reagent that ready for the use in Click Chemistry reaction which available as 10 mM solution in DMSO. As Cy5.5 azide is a far-red emitting dye, it can replace Alexa Fluor 680, and DyLight 680. |
|||
Cy5.5 maleimide (non-sulfonated) |
|||
| A8140-25 | ApexBio | 25 mg | 630 EUR |
|
Description: Cy5.5 maleimide is a thiol reactive dye which is capable of selective labeling of proteins which contain sulfhydryl groups. Cy5.5 maleimide has near infrared emission that makes it suitable for bioimaging applications. |
|||
Cy5.5 maleimide (non-sulfonated) |
|||
| A8140-5 | ApexBio | 5 mg | 351.6 EUR |
|
Description: Cy5.5 maleimide is a thiol reactive dye which is capable of selective labeling of proteins which contain sulfhydryl groups. Cy5.5 maleimide has near infrared emission that makes it suitable for bioimaging applications. |
|||
CY5.5-PEG-SH,10K |
|||
| FL079003-10K-50mg | Biochempeg | 50mg | 652.8 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-SH,1K |
|||
| FL079003-1K-50mg | Biochempeg | 50mg | 652.8 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-SH,20K |
|||
| FL079003-20K-50mg | Biochempeg | 50mg | 652.8 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-SH,2K |
|||
| FL079003-2K-50mg | Biochempeg | 50mg | 652.8 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-SH,3.4K |
|||
| FL079003-3.4K-50mg | Biochempeg | 50mg | 652.8 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-SH,5K |
|||
| FL079003-5K-50mg | Biochempeg | 50mg | 652.8 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-FA,10k |
|||
| FL079057-10K-100mg | Biochempeg | 100mg | 948 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-FA,20k |
|||
| FL079057-20K-100mg | Biochempeg | 100mg | 948 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-FA,2k |
|||
| FL079057-2K-100mg | Biochempeg | 100mg | 948 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-FA,3.4k |
|||
| FL079057-3.4K-100mg | Biochempeg | 100mg | 948 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CY5.5-PEG-FA,5k |
|||
| FL079057-5K-100mg | Biochempeg | 100mg | 948 EUR |
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
CD16 antibody (PE-CY5.5) |
|||
| 61R-CD16gMSPEC5 | Fitzgerald | 100 ug | 418.8 EUR |
|
Description: Rat monoclonal CD16 antibody (PE-CY5.5) |
|||
CD19 antibody (PE-CY5.5) |
|||
| 61R-CD19aMSPEC5 | Fitzgerald | 100 ug | 418.8 EUR |
|
Description: Rat monoclonal CD19 antibody (PE-CY5.5) |
|||
CD19 antibody (PE-CY5.5) |
|||
| 61R-CD19cHUPEC5 | Fitzgerald | 100 tests | 457.2 EUR |
|
Description: Mouse monoclonal CD19 antibody (PE-CY5.5) |
|||
CD19 antibody (PE-CY5.5) |
|||
| 61R-CD19dMSPEC5 | Fitzgerald | 100 ug | 483.6 EUR |
|
Description: Mouse monoclonal CD19 antibody (PE-CY5.5) |
|||
CD3 antibody (PE-CY5.5) |
|||
| 61R-CD3gHUPEC5 | Fitzgerald | 100 tests | 457.2 EUR |
|
Description: Mouse monoclonal CD3 antibody (PE-CY5.5) |
|||
CD45.1 antibody (PE-CY5.5) |
|||
| 61R-CD45gMSPEC5 | Fitzgerald | 100 ug | 548.4 EUR |
|
Description: Mouse monoclonal CD45.1 antibody (PE-CY5.5) |
|||
CD45.2 antibody (PE-CY5.5) |
|||
| 61R-CD45hMSPEC5 | Fitzgerald | 100 ug | 548.4 EUR |
|
Description: Mouse monoclonal CD45.2 antibody (PE-CY5.5) |
|||
CD45R antibody (PE-CY5.5) |
|||
| 61R-CD45RcMSPE5 | Fitzgerald | 100 ug | 483.6 EUR |
|
Description: Rat monoclonal CD45R antibody (PE-CY5.5) |
|||
CD4 antibody (Allophycocyanin-CY5.5) |
|||
| 61R-CD4eMSAPC5 | Fitzgerald | 100 ug | 379.2 EUR |
|
Description: Rat monoclonal CD4 antibody (Allophycocyanin-CY5.5) |
|||
CD4 antibody (PE-CY5.5) |
|||
| 61R-CD4eMSPEC5 | Fitzgerald | 100 ug | 457.2 EUR |
|
Description: Rat monoclonal CD4 antibody (PE-CY5.5) |
|||
CD4 antibody (PE-CY5.5) |
|||
| 61R-CD4kHUPEC5 | Fitzgerald | 100 tests | 457.2 EUR |
|
Description: Mouse monoclonal CD4 antibody (PE-CY5.5) |
|||
CD56 antibody (PE-CY5.5) |
|||
| 61R-CD56bHUPEC5 | Fitzgerald | 100 tests | 522 EUR |
|
Description: Mouse monoclonal CD56 antibody (PE-CY5.5) |
|||
CD8a antibody (PE-CY5.5) |
|||
| 61R-CD8abMSPEC5 | Fitzgerald | 100 ug | 418.8 EUR |
|
Description: Rat monoclonal CD8a antibody (PE-CY5.5) |
|||
Annexin V-Cy5.5 conjugate |
|||
| 20067 | AAT Bioquest | 100 Tests | 262.8 EUR |
Cy5.5 hydrazide (non-sulfonated) |
|||
| A8261-1 | ApexBio | 1 mg | 212.4 EUR |
|
Description: Cy5.5 hydrazide is a reactive dye for the labeling of biomolecules containing carbonyl groups, such as ketone and aldehydes. This dye pocesses a hydrazide group that can be used to label glycans at their reducing end or other reducing sugars, forming a hydrazone linkage. |
|||
Cy5.5 hydrazide (non-sulfonated) |
|||
| A8261-25 | ApexBio | 25 mg | 630 EUR |
|
Description: Cy5.5 hydrazide is a reactive dye for the labeling of biomolecules containing carbonyl groups, such as ketone and aldehydes. This dye pocesses a hydrazide group that can be used to label glycans at their reducing end or other reducing sugars, forming a hydrazone linkage. |
|||
Cy5.5 hydrazide (non-sulfonated) |
|||
| A8261-5 | ApexBio | 5 mg | 351.6 EUR |
|
Description: Cy5.5 hydrazide is a reactive dye for the labeling of biomolecules containing carbonyl groups, such as ketone and aldehydes. This dye pocesses a hydrazide group that can be used to label glycans at their reducing end or other reducing sugars, forming a hydrazone linkage. |
|||
Cy5.5 hydrazide (non-sulfonated) |
|||
| A8261-50 | ApexBio | 50 mg | 1027.2 EUR |
|
Description: Cy5.5 hydrazide is a reactive dye for the labeling of biomolecules containing carbonyl groups, such as ketone and aldehydes. This dye pocesses a hydrazide group that can be used to label glycans at their reducing end or other reducing sugars, forming a hydrazone linkage. |
|||
CD45.1 Antibody (PerCP-Cy5.5) |
|||
| 20-abx200805 | Abbexa |
|
|
CD45.2 Antibody (PerCP-Cy5.5) |
|||
| 20-abx200813 | Abbexa |
|
|
CD45RB Antibody (PerCP-Cy5.5) |
|||
| 20-abx200831 | Abbexa |
|
|
CD90.2 Antibody (PerCP-Cy5.5) |
|||
| 20-abx200919 | Abbexa |
|
|
H2Db Antibody (PerCP-Cy5.5) |
|||
| 20-abx200944 | Abbexa |
|
|
H2Dd Antibody (PerCP-Cy5.5) |
|||
| 20-abx200952 | Abbexa |
|
|
Ly6G Antibody (PerCP-Cy5.5) |
|||
| 20-abx201008 | Abbexa |
|
|
Ly6C Antibody (PerCP-Cy5.5) |
|||
| 20-abx201023 | Abbexa |
|
|
Streptavidin-PE-Cy5.5 conjugate |
|||
| SV-PEC5-100 | Alpha Diagnostics | 100 tests | 343.2 EUR |
Amersham Cy5.5 Maleimide 25mg |
|||
| PA15636 | Scientific Laboratory Supplies | EACH | 3339.06 EUR |
Cy5.5 NHS ester (non-sulfonated) |
|||
| A8103-25 | ApexBio | 25 mg | 630 EUR |
|
Description: Cyanine5.5 NHS ester is a reactive dye for the labeling of peptides, proteins, and oligonucleotides that contain amino-groups. Cy5.5-NHS ester is a near-infrared fluorescence dye able to dissolve in DMF and DMSO with the excitation maximum and emission maximum around 675 nm and 693 nm respectively. |
|||
Cy5.5 NHS ester (non-sulfonated) |
|||
| A8103-5 | ApexBio | 5 mg | 351.6 EUR |
|
Description: Cyanine5.5 NHS ester is a reactive dye for the labeling of peptides, proteins, and oligonucleotides that contain amino-groups. Cy5.5-NHS ester is a near-infrared fluorescence dye able to dissolve in DMF and DMSO with the excitation maximum and emission maximum around 675 nm and 693 nm respectively. |
|||
Cy5.5 carboxylic acid (non-sulfonated) |
|||
| A8134-25 | ApexBio | 25 mg | 630 EUR |
|
Description: Cy5.5 carboxylic acid is an un-activated labeling regent which has low aqueous solubility. For biomolecule labeling, the labeling reagent has low aqueous solubility, using of organic co-solvent to dissolve this molecular is necessary for efficient reaction |
|||
Cy5.5 carboxylic acid (non-sulfonated) |
|||
| A8134-5 | ApexBio | 5 mg | 351.6 EUR |
|
Description: Cy5.5 carboxylic acid is an un-activated labeling regent which has low aqueous solubility. For biomolecule labeling, the labeling reagent has low aqueous solubility, using of organic co-solvent to dissolve this molecular is necessary for efficient reaction |
|||
Sialoadhesin (CD169) Antibody (PerCP-Cy5.5) |
|||
| 20-abx200718 | Abbexa |
|
|
CD16+CD32 Antibody (PerCP-Cy5.5) |
|||
| 20-abx200726 | Abbexa |
|
|
B220 / CD45R Antibody (PerCP-Cy5.5) |
|||
| 20-abx200837 | Abbexa |
|
|
NK-1.1 Antibody (PerCP-Cy5.5) |
|||
| 20-abx201031 | Abbexa |
|
|
TCR beta Antibody (PerCP-Cy5.5) |
|||
| 20-abx201039 | Abbexa |
|
|
Anti-Hu CD15 PerCP-Cy5.5 |
|||
| T9-138-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu IgD PerCP-Cy5.5 |
|||
| T9-142-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD45 PerCP-Cy5.5 |
|||
| T9-160-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD3 PerCP-Cy5.5 |
|||
| T9-173-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD3 PerCP-Cy5.5 |
|||
| T9-173-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD22 PerCP-Cy5.5 |
|||
| T9-175-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD22 PerCP-Cy5.5 |
|||
| T9-175-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD279 PerCP-Cy5.5 |
|||
| T9-176-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD274 PerCP-Cy5.5 |
|||
| T9-177-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD7 PerCP-Cy5.5 |
|||
| T9-206-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD7 PerCP-Cy5.5 |
|||
| T9-206-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD8 PerCP-Cy5.5 |
|||
| T9-207-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD8 PerCP-Cy5.5 |
|||
| T9-207-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD10 PerCP-Cy5.5 |
|||
| T9-209-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD10 PerCP-Cy5.5 |
|||
| T9-209-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD15 PerCP-Cy5.5 |
|||
| T9-213-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD15 PerCP-Cy5.5 |
|||
| T9-213-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD25 PerCP-Cy5.5 |
|||
| T9-218-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD25 PerCP-Cy5.5 |
|||
| T9-218-T100 | ExBio | 100 tests | 422.4 EUR |
Anti-Hu CD45 PerCP-Cy5.5 |
|||
| T9-222-T025 | ExBio | 25 tests | 235.2 EUR |
Anti-Hu CD45 PerCP-Cy5.5 |
|||
| T9-222-T100 | ExBio | 100 tests | 422.4 EUR |
In our earlier report, the predominant emm kind was emm12, whereas within the present examine, emm1 was the commonest. The present examine additionally recognized Three strains of Group G Streptococcus (GGS) among the many isolates, which carried a stg245, stg6795, and stg840 gene, respectively. One GAS pressure was discovered to hold stg485, a gene usually related to GGS slightly than GAS.